Aptamer Group has reported a strong first half, with revenue rising 27% year on year to £830,000 in the six months to December 2025.

The AIM-listed life sciences company said it is making good progress towards a more recurring, high-margin revenue model, supported by a £2 million fee-for-service order book and a £3.1m sales pipeline.

During the period, the York-based MedTech signed multiple licensing agreements with partners including Twist Bioscience and Alphazyme, marking a shift from development to commercialisation.

The company said it remains confident that full-year revenue will materially exceed that of last year.